Upstream Bio, Inc. (UPB)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration revenue | 937 | 566 | 607 | |
| Research and development | 37,865 | 25,797 | 15,433 | |
| General and administrative | 7,419 | 6,782 | 4,067 | |
| Total operating expenses | 45,284 | 32,579 | 19,500 | |
| Loss from operations | -44,347 | -32,013 | -18,893 | |
| Interest income | 4,431 | 4,743 | 2,904 | |
| Other expense, net | -50 | - | -3 | |
| Change in fair value of preferred stock tranche right liabilities | - | - | - | |
| Total other income, net | 4,381 | 4,743 | 2,901 | |
| Net loss | -39,966 | -27,270 | -15,992 | |
| Redeemable convertible preferred stock cumulative dividends | - | - | 5,041 | |
| Net loss attributable to common stockholders | -39,966 | -27,270 | -21,033 | |
| Earnings per share, basic, total | -0.74 | -0.51 | -6.96 | |
| Earnings per share, diluted, total | -0.74 | -0.51 | -6.96 | |
| Weighted average number of shares outstanding, basic | 53,770,868 | 53,617,723 | 3,023,155 | |
| Weighted average number of shares outstanding, diluted | 53,770,868 | 53,617,723 | 3,023,155 | |